Montreal cancer drug developer Repare strikes US$1-billion-plus deal with Roche
theglobeandmail.com
business
2022-06-02 10:29:14

Montreal cancer drug developer Repare Therapeutics Inc. RPTX-Q has struck a deal with pharmaceutical giant F. Hoffman-La Roche AG that could be worth north of US$1-billion to the Canadian startup.Repare revealed after the close of markets Wednesday that it had entered into a worldwide license and collaboration agreement with Roche to develop and commercialize the Montreal company's drug camonsertib, also known as RP-3500.RP-3500 is the lead molecule of a series of 'precision oncology' drugs Repare is developing that attack genetic defects in cancerous tumours, preventing toxic cells from repairing their DNA.
